No phaseRecruitingAge-related condition

Sequential Zoledronic Acid at 3 Months Versus 6 Months After Discontinuation of Long-term Denosumab Therapy in Patients with Primary Osteoporosis: A Prospective, Open-label, Randomized Controlled Trial

Comparison of Bone Mineral Density Maintenance Efficacy of Sequential Zoledronic Acid at Different Time Windows (3 Months vs. 6 Months) After Discontinuation of Long-term Denosumab Therapy in Patients with Primary Osteoporosis: A Prospective, Open-label, Superiority, Randomized Controlled Trial

Sponsor

Tongji Hospital of Tongji University

Enrollment

65 planned

Conditions

Primary osteoporosis; Postmenopausal osteoporosis; Osteoporosis in men

Interventions

Zoledronic acid administered 6 months after the last denosumab injection; Zoledronic acid administered 3 months after the last denosumab injection

Ages

adults, older adults

Registry

ChiCTR2600130359

Full record on the Chinese Clinical Trial RegistrySource: WHO ICTRP, processed August 24, 2026